News
News Home
Quick Bites
Exploradio
News Archive
News Channel
Special Features
NPR
nowplaying
On AirNewsClassical
Loading...
  
School Closings
WKSU Support
Funding for WKSU is made possible in part through support from the following businesses and organizations.

Akron General

Wayside Furniture


For more information on how your company or organization can support WKSU, download the WKSU Media Kit.

(WKSU Media Kit PDF icon )


Donate Your Vehicle to WKSU

Programs Schedule Make A Pledge Member BenefitsFAQ/HelpContact Us
Health and Medicine


Change in FDA policy fast tracks testing of Alzheimer's drug
But other scientists are unable to reproduce dramatic improvements shown in preliminary tests in Cleveland
by WKSU's JEFF ST. CLAIR


Reporter / Host
Jeff St. Clair
 
Dr. Gary Landeth (right) hopes to prove that Bexarotene can treat Alzheimer’s disease through phase 1 clinical trials. He and then graduate student Paige Cramer started a company called Rexceptor to develop the drug for clinical use.
Courtesy of Jeff St.Clair
Download (WKSU Only)
In The Region:

A promising new treatment for Alzheimer’s disease developed in Cleveland has run into some roadblocks, but backers of a repurposed drug are moving forward with clinical trials.

LISTEN: ST.CLAIR ON ALZHEIMER'S DRUG

Other options:
Windows Media / MP3 Download (1:04)


The drug Bexarotene was originally used to treat skin cancer. But Gary Landreth, a neuroscientist at Case Western Reserve University, showed last year that mice bred to have Alzheimer’s disease dramatically improved when given the drug. Now Landreth is ready to test it on people.

He says a recent change in FDA policy allows the drug to be tested on healthy people to determine whether it reduces soluble amyloid beta proteins that are believed to lead to Alzheimer’s.

“The FDA has recognized we now need to treat people who are at risk of Alzheimer’s disease but are cognitively normal, and that changes everything,” Landreth says.

The scientific community, however, is not convinced the drug actually works. Last week, the journal "Science" published independent studies that failed to reproduce Landreth’s dramatic results. However, he says he is still holding out hope his original findings in mice will be validated.

“Proving this mechanism in humans is essential to any subsequent development of the drug,” Landreth says.

Landreth says he could know by the end of the year whether Bexarotene will move on to further testing or join the dozens of other would-be Alzheimer treatments littering the path to a cure.

Listener Comments:

Does anyone have any idea as to what dosage they will be testing?


Posted by: DICKY_DOOO on May 28, 2013 4:05AM
Add Your Comment
Name:

Location:

E-mail: (not published, only used to contact you about your comment)


Comments:




 
Page Options

Print this page

E-Mail this page / Send mp3

Share on Facebook




Stories with Recent Comments

An amendment to an Ohio agriculture bill may kill whole bill
I hope the Gov. sticks to his veto, Att takes more out of this state than it puts in.

From warehouse to writer: Terry Pluto's Thanksgiving thank you
Dear Terry: On my 8th cup of coffee trying to get Thanksgiving "Brunch" done ahead of time because I work nights. However, I just had to stop to contact yo...

The first big private gift comes in for the pro football HOF project
The HOF has needed a shot in the arm for many years and this project will go a long way to getting the attraction the attention it deserves (next: upgrad...

Environmental study nears completion in East Liverpool
Twenty years ago my twin sister and I protested the building and operation of the WTI facility citing several studies that indicated the risk of cancer due to ...

HOF's Canton expansion could take an island and make it a village
I live in the block from Broad St to the Hall of Fame and will be impacted by the expansion. I am in the process of selling my home and planned to long before i...

Cleveland redeploys police to replace rejected red-light traffic cameras
Periodic rotational enforcement without warning does NOT change behavior and the city officials know that. This is the basis of all officer-run enforcement trap...

New enrollment period offers more insurance options
The removal of federal funding for healthcare CO-OPs may limit the growth of the CO-OP movement. http://www.healthcaretownhall.com/?p=6381

The family of Boardman vet killed in Vietnam receives his medals
My name is Mike Eisenbraun. I am Larry's brother. I was 14 years old when Larry was killed in Vietnam. He has been gone for 46 years but it seems like yester...

Cleveland seniors are creating new wealth -- and facing new challenges
Why is anyone surprised that we people over 65 are not retiring? If you have been paying attention, defined company funded pensions were phasing out in the eigh...

Copyright © 2014 WKSU Public Radio, All Rights Reserved.

 
In Partnership With:

NPR PRI Kent State University

listen in windows media format listen in realplayer format Car Talk Hosts: Tom & Ray Magliozzi Fresh Air Host: Terry Gross A Service of Kent State University 89.7 WKSU | NPR.Classical.Other smart stuff. NPR Senior Correspondent: Noah Adams Living on Earth Host: Steve Curwood 89.7 WKSU | NPR.Classical.Other smart stuff. A Service of Kent State University